Cas:53172-84-2 pent-2-en-2-ylbenzene manufacturer & supplier

Chemical Name:pent-2-en-2-ylbenzene

CAS.NO:53172-84-2

Synonyms:2-phenyl-2-pentene;2-Phenyl-pent-2-en;2-phenylpent-2-ene

Molecular Formula:C₁₁H₁₄

Molecular Weight:146.22900

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:204ºC at 760 mmHg

Density:0.876g/cm3

Index of Refraction:1.512

PSA:

Exact Mass:146.11000

LogP:3.49990

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-phenyl-2-pentene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-phenylpent-2-ene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-phenyl-2-pentene Use and application,2-phenyl-2-pentene technical grade,usp/ep/jp grade.

Related News: The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. pent-2-en-2-ylbenzene manufacturer The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. pent-2-en-2-ylbenzene supplier Active Pharmaceutical Ingredients (APIs): Pharmaceutical active ingredients, which are the basic substances that constitute the pharmacological effects of pharmaceuticals, and are prepared by chemical synthesis, plant extraction, or biotechnology. pent-2-en-2-ylbenzene vendor The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. pent-2-en-2-ylbenzene factory This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?